Sort
39,280 grants matching “leukemia”
Pharmacogenomics to Catalyze Decision Support in Oncology Care
$867,862Peter Hugh O'Donnell · University Of Chicago · R01 · FY2024 · HG
CANCER AND INFLAMMATION: FUNCTION AND THERAPY
$867,725Michael Dean · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
CANCER AND INFLAMMATION GENETICS
$867,725Michael Dean · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Mitigating Long-term Treatment-related Morbidity in Childhood Cancer Survivors
$867,671Smita Bhatia · University Of Alabama At Birmingham · R35 · FY2018 · CA
NON-ACUTE RETROVIRUSES AND DETERMINANTS OF ONCOGENICITY
$867,470University Of Pennsylvania · P01 · FY2000 · CA
Pharmacogenomics to Catalyze Decision Support in Oncology Care
$867,396Peter Hugh O'Donnell · University Of Chicago · R01 · FY2025 · HG
A FUNCTIONAL GENOMICS HEART &LUNG DEVELOP. PROGRAM
$867,210Children'S Research Institute · U01 · FY2002 · HL
Molecular and Cellular Regulation of Pre-Leukemic Stem Cells and their Therapeutic Targeting
$866,743Ulrich Steidl · Albert Einstein College Of Medicine · R35 · FY2023 · CA
Elicitation of HIV Broadly Neutralizing Antibodies from Engineered B cells
$866,189James Even Voss · Scripps Research Institute, The · R01 · FY2024 · AI
Genomic Classification of Human Liver Cancer
$865,803Snorri Thorgeirsson · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
NON-ACUTE RETROVIRUSES AND DETERMINANTS OF ONCOGENICITY
$865,488University Of Pennsylvania · P01 · FY2002 · CA
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
$865,308Avinash Desai · Actinium Pharmaceuticals, Inc. · R42 · FY2023 · CA
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
$865,308Avinash Desai · Actinium Pharmaceuticals, Inc. · R42 · FY2024 · CA
Characterizing pediatric genomes through an optimized sequencing approach
$865,000Shawn E Levy · Hudson-Alpha Institute For Biotechnology · U24 · FY2018 · HD
Innovation of Biobanking for Cellular Adoptive Immunotherapies Based on a First-in-Class Biocompatible Cryopreservation Technology for T and NK Cells and Their CAR-Engineered Products
$864,173Xu Han · Cryocrate, Llc · R44 · FY2023 · CA
Biological Functions of Chromosomal Proteins
$864,126Michael Bustin · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
TET enzymes as guardians of genome stability
$864,061Anjana Rao · La Jolla Institute For Immunology · R35 · FY2016 · CA
Biostatistics Shared Resources Core
$863,560Motomi Mori · St. Jude Children'S Research Hospital · P30 · FY2020 · CA
Biostatistics Shared Resources Core
$863,560Motomi Mori · St. Jude Children'S Research Hospital · P30 · FY2023 · CA
Biostatistics Shared Resources Core
$863,560Motomi Mori · St. Jude Children'S Research Hospital · P30 · FY2022 · CA
Information flow and state transitions at the system and multi-dimensional scales in leukemia progression
$863,194Russell Christian Rockne · Beckman Research Institute/City Of Hope · U01 · FY2022 · CA
BioRad Galactomannan EIA for Diagnosis of Aspergillosis
$862,921Fred Hutchinson Cancer Research Center · U01 · FY2004 · AI
BCMA Specific Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Patients with Multiple Myeloma
$862,729Damian J. Green · Fred Hutchinson Cancer Center · P01 · FY2022 · CA
Impact of Infection and Inflammation on Primitive Hematopoiesis
$862,071Katherine Yudeh King · Baylor College Of Medicine · R35 · FY2022 · HL
BCMA Specific Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Patients with Multiple Myeloma
$861,992Damian J. Green · Fred Hutchinson Cancer Research Center · P01 · FY2020 · CA